DEFA14A: Patterson Companies to be Acquired by Patient Square Capital in $4.1 Billion Deal

Patterson Companies has agreed to be acquired by Patient Square Capital for $31.35 per share in cash, valuing the transaction at approximately $4.1 billion.

Summary

• Patterson Companies, a leading dental and animal health distributor, has entered into a definitive agreement to be acquired by Patient Square Capital.
• The acquisition price is $31.35 per share in cash, representing a 49% premium to the 30-day volume-weighted average price ending December 4, 2024.
• The total transaction value is approximately $4.1 billion, including the refinancing of Patterson's receivables facilities.
• The transaction is expected to close in the fourth quarter of Patterson's fiscal year 2025.
• The deal is subject to shareholder and regulatory approvals, as well as other customary closing conditions.
• Patient Square Capital will finance the acquisition through a combination of equity and debt financing.
• The merger agreement includes a 40-day go-shop period allowing Patterson to solicit alternative acquisition proposals.
• Upon completion, Patterson will become a privately held company and its stock will be delisted from the NASDAQ.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment, highlighting the benefits for shareholders and the company's future growth prospects. The high premium and the involvement of reputable financial institutions contribute to the positive outlook.

Positives

• The acquisition provides immediate and certain value for Patterson shareholders.
• The transaction allows Patterson to continue investing in its customers and driving growth.
• Patient Square Capital shares a long-term vision for Patterson and is considered an excellent partner.
• The deal includes a go-shop period, allowing the company to explore other potential offers.

Negatives

• The company will be delisted from the NASDAQ and become privately held.
• The transaction is subject to shareholder and regulatory approvals, which could introduce uncertainty.

Risks

• The merger may not be completed within the anticipated timeframe or at all.
• Failure to obtain required regulatory and shareholder approvals could prevent the merger.
• The merger could disrupt current plans and operations or divert management's attention.
• The merger could affect the company's ability to retain key personnel and maintain relationships.
• The stock price may decline significantly if the merger is not completed.
• Legal proceedings related to the merger could arise.
• The company is dependent on suppliers and faces risks related to distribution, sales, and technology.
• The company faces risks related to competition, market consolidation, and changing consumer demand.
• The company is exposed to risks in the healthcare industry, including regulatory changes and litigation.

Future Outlook

The transaction is expected to close in the fourth quarter of Patterson's fiscal 2025, subject to shareholder and regulatory approvals and other customary closing conditions. Patterson will become a privately held company upon completion of the transaction.

Management Comments

• Don Zurbay, President and Chief Executive Officer of Patterson, stated that the transaction delivers immediate and certain value for shareholders and positions the company to continue to invest in serving customers and driving growth.
• Jim Momtazee, Managing Partner at Patient Square, expressed admiration for Patterson and excitement to work with management on the next chapter of growth.

Industry Context

This acquisition reflects the ongoing trend of private equity firms investing in healthcare distribution companies. The deal also highlights the value of established brands and strong management teams in the dental and animal health sectors.

Comparison to Industry Standards

• The 49% premium offered to Patterson shareholders is significant, suggesting a strong valuation by Patient Square Capital.
• Comparable transactions in the healthcare distribution space have seen varying premiums, but this deal appears to be on the higher end.
• The involvement of major financial institutions like Citi, UBS, and Wells Fargo in the debt financing is typical for deals of this size.
• The inclusion of a go-shop period is a common practice in such transactions, allowing the company to explore other potential offers.

Stakeholder Impact

• Shareholders will receive $31.35 per share in cash.
• Employees will continue to be employed by the new private company.
• Customers and suppliers will continue to have relationships with Patterson.
• Creditors will be refinanced as part of the transaction.

Next Steps

• Patterson will prepare and file a proxy statement with the SEC.
• A special shareholder meeting will be held to vote on the adoption of the merger agreement.
• The company will seek regulatory approvals.
• Patterson will cooperate with Parent in connection with the debt financing for the transaction.
• The company will use reasonable best efforts to obtain regulatory approvals.

Key Dates

Keywords

acquisition, merger, Patterson Companies, Patient Square Capital, dental distribution, animal health distribution, private equity, go-shop, delisting, shareholder approval